Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2020-03-05 Share Issue/Capital Cha…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 3G 13 pages 247.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX (Australian Securities Exchange) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of new unquoted options as consideration for services rendered, including specifics such as the number of securities, security description, and the purpose of the issue. This type of filing is a formal announcement related to changes in the company's capital structure, specifically the issuance of new securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is the actual notification, not just a brief announcement or reference to another report.
2020-03-05 English
Half Yearly Report and Accounts 27 pages 461.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Genetic Technologies Limited Appendix 4D Half-year 31 December 2019' and contains detailed financial information for the half-year period ending 31 December 2019. It includes a directors' report, interim financial statements such as profit or loss, balance sheet, cash flows, notes to the financial statements, and an auditor's review report. The document explicitly states it is an 'Interim report - 31 December 2019' and references the Corporations Act 2001, which aligns with regulatory requirements for interim financial reporting. The content is comprehensive and includes actual financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the length (15,000 characters) supports it being a full report rather than a brief announcement. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2020
2020-02-26 English
Quarterly Activities Report & Appendix 4C 8 pages 377.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2019' and contains detailed financial data including cash flow statements, operational highlights, capital raising activities, and compliance statements. It is a comprehensive report covering a fiscal quarter, with actual financial statements and analysis, not just an announcement or summary. The presence of Appendix 4C, which is a standard quarterly report format for entities listed on the ASX, confirms this is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2020-01-30 English
Change in substantial holding 6 pages 239.2KB
Regulatory Filings
2020-01-15 English
Change in substantial holding 5 pages 253.1KB
Regulatory Filings
2020-01-13 English
JP Morgan Biotech Showcase Investor Presentation 42 pages 8.7MB
Investor Presentation Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited providing a corporate and strategic update, including details about a presentation at the 2020 JP Morgan Biotech Showcase. It includes extensive company background, product information, intellectual property details, and forward-looking statements. The document is a detailed presentation aimed at investors and stakeholders about the company's strategy, products, and market positioning. It is not a financial report, earnings release, or regulatory filing. The presence of slides and detailed company and product information aligns with an Investor Presentation. The document length (15,000 characters) and content confirm it is the presentation itself, not just an announcement of a report. Therefore, the appropriate classification is Investor Presentation (IP).
2020-01-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.